Cargando…

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma

BACKGROUND: Renal cell carcinoma (RCC) is highly resistant to chemotherapy because of a high apoptotic threshold. Recent evidences suggest that GSK-3β positively regulates human pancreatic cancer and leukaemia cell survival in part through regulation of nuclear factor (NF-κB)-mediated expression of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bilim, V, Ougolkov, A, Yuuki, K, Naito, S, Kawazoe, H, Muto, A, Oya, M, Billadeau, D, Motoyama, T, Tomita, Y
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795437/ https://www.ncbi.nlm.nih.gov/pubmed/19920820 http://dx.doi.org/10.1038/sj.bjc.6605437

Ejemplares similares

Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis
por: Bilim, V, et al.
Publicado: (2008)

Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma
por: Yu, H, et al.
Publicado: (2015)

LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2017)

Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression
por: Yamana, K, et al.
Publicado: (2005)

Identification of thymidylate synthase as a potential therapeutic target for lung cancer
por: Takezawa, K, et al.
Publicado: (2010)

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
por: Mahalingam, D, et al.
Publicado: (2011)

Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas
por: Rahman, M T, et al.
Publicado: (2012)

STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma
por: Horiguchi, A, et al.
Publicado: (2010)

Fatty acid synthase: a novel target for antiglioma therapy
por: Zhao, W, et al.
Publicado: (2006)

The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas
por: Seguin, F, et al.
Publicado: (2012)

Purinergic regulation of angiogenesis by human breast carcinoma-secreted nucleoside diphosphate kinase
por: Rumjahn, S M, et al.
Publicado: (2007)

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer
por: Takezawa, K, et al.
Publicado: (2011)

Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas
por: Farace, P, et al.
Publicado: (2009)

Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas
por: Dahse, R, et al.
Publicado: (2009)

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels
por: Giovannetti, E, et al.
Publicado: (2007)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

Upregulation of calcium-sensing receptor and mitogen-activated protein kinase signalling in the regulation of growth and differentiation in colon carcinoma
por: Bhagavathula, N, et al.
Publicado: (2005)

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts
por: Wang, X, et al.
Publicado: (2013)

Insulin Reduces Cerebral Ischemia/Reperfusion Injury in the Hippocampus of Diabetic Rats: A Role for Glycogen Synthase Kinase-3β
por: Collino, Massimo, et al.
Publicado: (2009)

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma
por: Santos, C D, et al.
Publicado: (2015)

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
por: Donskov, Frede, et al.
Publicado: (2015)

Expression of thymidylate synthase in human cells is an early G(1) event regulated by CDK4 and p16INK4A but not E2F
por: Le François, B G, et al.
Publicado: (2007)

Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours
por: Beloueche-Babari, M, et al.
Publicado: (2015)

The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence
por: Sun, C K, et al.
Publicado: (2007)

Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance
por: Leung, E L, et al.
Publicado: (2008)

Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy
por: Griffiths, R W, et al.
Publicado: (2005)

Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer
por: Tanaka, N, et al.
Publicado: (2011)

Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells
por: Tao, Y, et al.
Publicado: (2007)

Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?
por: Dolley-Hitze, T, et al.
Publicado: (2010)

Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells
por: D'Amato, C, et al.
Publicado: (2014)

TCTP as a therapeutic target in melanoma treatment
por: Boia-Ferreira, M, et al.
Publicado: (2017)

Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours
por: Green, J, et al.
Publicado: (2006)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
por: Tavanti, E, et al.
Publicado: (2013)

Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance
por: Kaliszczak, M, et al.
Publicado: (2013)

MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model
por: Diaz-Montero, C Marcela, et al.
Publicado: (2016)

Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
por: Voss, Martin H, et al.
Publicado: (2016)

CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma
por: Fukusumi, T, et al.
Publicado: (2014)

Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array
por: Perez-Gracia, J L, et al.
Publicado: (2009)

Cell migration in paediatric glioma; characterisation and potential therapeutic targeting
por: Cockle, J V, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4lcuscf1aqsqfpmhfiph8de8g9